Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 8 May 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The core agricultural chemical intermediates are generally expected to perform in line with the initial plan, while functional intermediates are expected to generate higher revenue due to the introduction of new products. Pharmaceutical intermediates, however, are expected to decline significantly due to customers’ inventory adjustments. In terms of earnings, income at each stage is expected to exceed the previous forecast as a result of efforts to introduce high-value-added new products, reduce expenses and lower costs.
| Item | Details |
|---|---|
| Net Sales | ¥6,650 million → ¥6,432 million（-3.3%） |
| Operating profit | ¥350 million → ¥489 million（+39.8%） |
| Ordinary income | ¥430 million → ¥578 million（+34.6%） |
| Profit attributable to owners of the parent | ¥300 million → ¥461 million（+53.7%） |
| Net income per share | 229.63 yen and sen → 353 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 8 May 2025 |
| Previous-period results | Net Sales ¥6,622 million / Operating profit ¥541 million / Ordinary income ¥644 million / Net income for the current fiscal year ¥363 million / Net income per share ¥277.96 per share |
| Reason for the revision | The core agricultural chemical intermediates are generally expected to perform in line with the initial plan, while functional intermediates are expected to generate higher revenue due to the introduction of new products. Pharmaceutical intermediates, however, are expected to decline significantly due to customers’ inventory adjustments. In terms of earnings, income at each stage is expected to exceed the previous forecast as a result of efforts to introduce high-value-added new products, reduce expenses and lower costs. |
| Dividend forecast revision | The year-end dividend will be increased by ¥20 from ¥70 to ¥90 per share, and the annual dividend will be revised from ¥70 to ¥90 per share. This is subject to approval at the annual general meeting of shareholders scheduled for 23 June 2026. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The sales forecast was revised downward because pharmaceutical intermediates are expected to decline significantly due to customers’ inventory adjustments. Meanwhile, forecasts for income at each stage have been revised upward as a result of efforts to introduce high-value-added new products, reduce expenses and lower costs. The dividend was increased following the revision to the earnings forecasts.